Devopharma ApS: Financial statements 2019
CVR: 38968254
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Devopharma ApS (CVR 38968254) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125. Equity in the 2019 report amounted to DKK 43,750. The solvency ratio was 43.8%.
- Gross Profit
- DKK -3,125
- Profit/Loss
- DKK -3,125
- Equity
- DKK 43,750
- Total Assets
- DKK 100,000
- Employees
- 0
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Devopharma ApS has published its interim report for the period September 25, 2017 – December 31, 2018.
As of April 16, 2019, Morten Olesen has stepped down as director of Devopharma ApS.
As of April 16, 2019, Allan Anesteen Tharuman has stepped down as director of Devopharma ApS.
About Devopharma ApS
Devopharma ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company's owners include JARCO HOLDING ApS, HN HOLDING 2010 ApS and Friendly Holding ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2025 report amounted to DKK 25,000.